London · Delayed Price · Currency is GBP · Price in GBX Diaceutics Statistics
Total Valuation
Diaceutics has a market cap or net worth of GBP 121.08 million. The enterprise value is 114.89 million.
| Market Cap | 121.08M |
| Enterprise Value | 114.89M |
Important Dates
The last earnings date was Tuesday, May 26, 2026.
| Earnings Date | May 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Diaceutics has 84.67 million shares outstanding. The number of shares has increased by 0.80% in one year.
| Current Share Class | 84.67M |
| Shares Outstanding | 84.67M |
| Shares Change (YoY) | +0.80% |
| Shares Change (QoQ) | +1.38% |
| Owned by Insiders (%) | 23.21% |
| Owned by Institutions (%) | 47.16% |
| Float | 48.69M |
Valuation Ratios
The trailing PE ratio is 1,248.23 and the forward PE ratio is 147.27.
| PE Ratio | 1,248.23 |
| Forward PE | 147.27 |
| PS Ratio | 3.15 |
| PB Ratio | 2.99 |
| P/TBV Ratio | 4.96 |
| P/FCF Ratio | 109.28 |
| P/OCF Ratio | 102.70 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 26.25, with an EV/FCF ratio of 103.69.
| EV / Earnings | 1,184.40 |
| EV / Sales | 2.99 |
| EV / EBITDA | 26.25 |
| EV / EBIT | n/a |
| EV / FCF | 103.69 |
Financial Position
The company has a current ratio of 3.43, with a Debt / Equity ratio of 0.03.
| Current Ratio | 3.43 |
| Quick Ratio | 3.30 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.26 |
| Debt / FCF | 1.04 |
| Interest Coverage | 0.74 |
Financial Efficiency
Return on equity (ROE) is 0.24% and return on invested capital (ROIC) is 0.04%.
| Return on Equity (ROE) | 0.24% |
| Return on Assets (ROA) | 0.05% |
| Return on Invested Capital (ROIC) | 0.04% |
| Return on Capital Employed (ROCE) | 0.10% |
| Weighted Average Cost of Capital (WACC) | 9.09% |
| Revenue Per Employee | 187,498 |
| Profits Per Employee | 473 |
| Employee Count | 205 |
| Asset Turnover | 0.78 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Diaceutics has paid 205,000 in taxes.
| Income Tax | 205,000 |
| Effective Tax Rate | 67.88% |
Stock Price Statistics
The stock price has increased by +21.16% in the last 52 weeks. The beta is 0.89, so Diaceutics's price volatility has been lower than the market average.
| Beta (5Y) | 0.89 |
| 52-Week Price Change | +21.16% |
| 50-Day Moving Average | 160.20 |
| 200-Day Moving Average | 154.68 |
| Relative Strength Index (RSI) | 41.64 |
| Average Volume (20 Days) | 328,580 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Diaceutics had revenue of GBP 38.44 million and earned 97,000 in profits. Earnings per share was 0.00.
| Revenue | 38.44M |
| Gross Profit | 31.48M |
| Operating Income | 43,000 |
| Pretax Income | 302,000 |
| Net Income | 97,000 |
| EBITDA | 4.09M |
| EBIT | 43,000 |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
The company has 7.34 million in cash and 1.15 million in debt, with a net cash position of 6.19 million or 0.07 per share.
| Cash & Cash Equivalents | 7.34M |
| Total Debt | 1.15M |
| Net Cash | 6.19M |
| Net Cash Per Share | 0.07 |
| Equity (Book Value) | 40.48M |
| Book Value Per Share | 0.48 |
| Working Capital | 20.81M |
Cash Flow
In the last 12 months, operating cash flow was 1.18 million and capital expenditures -71,000, giving a free cash flow of 1.11 million.
| Operating Cash Flow | 1.18M |
| Capital Expenditures | -71,000 |
| Depreciation & Amortization | 4.04M |
| Net Borrowing | -333,000 |
| Free Cash Flow | 1.11M |
| FCF Per Share | 0.01 |
Margins
Gross margin is 81.90%, with operating and profit margins of 0.11% and 0.25%.
| Gross Margin | 81.90% |
| Operating Margin | 0.11% |
| Pretax Margin | 0.79% |
| Profit Margin | 0.25% |
| EBITDA Margin | 10.63% |
| EBIT Margin | 0.11% |
| FCF Margin | 2.88% |
Dividends & Yields
Diaceutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.80% |
| Shareholder Yield | -0.80% |
| Earnings Yield | 0.08% |
| FCF Yield | 0.92% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Diaceutics is 213.00, which is 43.92% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 213.00 |
| Price Target Difference | 43.92% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 20.39% |
| EPS Growth Forecast (3Y) | 122.93% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Diaceutics has an Altman Z-Score of 9.77 and a Piotroski F-Score of 5.
| Altman Z-Score | 9.77 |
| Piotroski F-Score | 5 |